Trio Of Diagnostics Execs Weigh In On Upcoming Challenges

episode

Citeline Podcasts not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Essentials: How to Assess & Improve All Aspects of Your Fitness | Dr. Andy Galpin 35 min · 17 Sep 2026 · Huberman Lab

#502 – Psychiatry, Insane Asylums, Mental Illness, ECT, Lobotomies, Freud & Jung 3h 43m · 17 Sep 2026 · Lex Fridman Podcast

Your partner wants profit. You want freedom. Now what? 22 min · 16 Sep 2026 · The Optometry Success Podcast

Board of County Supervisors Meeting - Work Session - Sep 15, 2026 3h 17m · 15 Sep 2026 · Prince William County Board of Supervisors

Finance and Budget Committee - Sep 15, 2026 1h 43m · 15 Sep 2026 · Prince William County Finance and Budget Committee

Sept. 15, 2026 Board of Supervisors Meeting 8h 46m · 15 Sep 2026 · Fairfax County Board of Supervisors

Report any issue

Source

Recorded06 Feb 2024

Publisherfeeds.soundcloud.com ↗

Handlerec:4678044

Show notes

During this episode, Barnaby Pickering is joined by Rollie Carlson, CEO of Immunexpress, developer of Septicyte, a test for sepsis, Mark McDonough, CEO of ChromaCode, a company developing multiple blood-based tests for cancer diagnosis and treatment, with its first being in non-small cell lung cancer, and Lishan Aklog, CEO of Lucid Diagnostics, who have developed a cell-collection method that aims to bring forward the stage at which oesophageal cancer can be diagnosed. The group discuss the companies’ products and why they are transformative, as well as the upcoming regulatory and commercial hurdles awaiting diagnostics companies.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in